{
    "name": "cerliponase alfa",
    "comment": "Rx",
    "other_names": [
        "Brineura",
        "recombinant human tripeptidyl peptidase 1 (rhtpp1)"
    ],
    "classes": [
        "Metabolic & Endocrine",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/brineura-recombinant-human-tripeptidyl-peptidase-1-rhtpp1-cerliponase-alfa-1000125",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant women to inform a drug-associated risk of pregnancy-related outcomes"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Any sign or symptom of acute, unresolved localized infection on or around the device insertion site (e.g. cellulitis or abscess); or suspected or confirmed CNS infection (e.g. cloudy CSF or positive CSF gram stain, or meningitis)",
                "Any acute intraventricular access device-related complication (e.g., leakage, extravasation of fluid, or device failure)",
                "Patients with ventriculoperitoneal shunts"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Must be administered using aseptic technique to reduce the risk of infection; healthcare professionals should inspect the scalp for skin integrity to ensure the intraventricular access device is not compromised prior to each infusion (see Administration)",
                "Monitor vital signs before infusion starts, periodically during infusion, and postinfusion in a healthcare setting",
                "Perform ECG monitoring during infusion in patients with a history of bradycardia, conduction disorder, or with structural heart disease, as some patients with CLN2 disease may develop conduction disorders or heart disease; in patients without cardiac abnormalities, regular 12-lead ECG evaluations should be performed every 6 months"
            ],
            "specific": [
                {
                    "type": "Hypersensitivity reactions",
                    "description": [
                        "Hypersensitivity reactions, including anaphylaxis, reported during infusion or within 24 hr of completion; observe patient during and after infusion; inform caregivers of signs and symptoms of anaphylaxis and instruct them to seek immediate medical care if these occur",
                        "Consider risks and benefits of readministration following anaphylactic reaction; if decision is made to readminister therapy after occurrence of anaphylaxis, ensure appropriately trained personnel and equipment for emergency resuscitation (including epinephrine and other emergency medicines) are readily available during infusion; initiate subsequent infusion at approximately one-half initial infusion rate at which anaphylactic reaction occurred"
                    ]
                },
                {
                    "type": "Intraventricular access complications",
                    "description": [
                        "Bacterial meningitis requiring antibiotic treatment and removal of device reported during postmarketing use; signs and symptoms of infections may not be readily apparent in patients with CLN2 disease; therapy should be administered by, or under direction of, physician experienced in intraventricular administration to reduce risk of infectious complications",
                        "Obtain a sample of CSF for cell count and culture prior to each infusion and when clinically indicated",
                        "Do not administer therapy if there are localized signs of infection on or around device insertion site, such as erythema, tenderness, or discharge or suspected or confirmed CNS infection (e.g. cloudy CSF or positive CSF gram stain, or meningitis)",
                        "Healthcare providers should be vigilant for development of signs and symptoms of infection, including meningitis, during treatment and monitor device insertion site for signs of infection",
                        "Consult a neurosurgeon for any complications with implanted device; in case of device-related complication, discontinue infusion and refer to device labeling for further instructions"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Pyrexia",
            "percent": "71"
        },
        {
            "name": "ECG abnormalities",
            "percent": "71"
        },
        {
            "name": "Decreased CSF protein",
            "percent": "71"
        },
        {
            "name": "Vomiting",
            "percent": "63"
        },
        {
            "name": "Seizures",
            "percent": "50"
        },
        {
            "name": "Hypersensitivity",
            "percent": "46"
        },
        {
            "name": "Increased CSF protein",
            "percent": "21"
        },
        {
            "name": "Hematoma",
            "percent": "21"
        },
        {
            "name": "Headache",
            "percent": "17"
        },
        {
            "name": "Irritability",
            "percent": "17"
        },
        {
            "name": "Pleocytosis",
            "percent": "17"
        },
        {
            "name": "Device",
            "percent": "8"
        },
        {
            "name": "related infection",
            "percent": "8"
        },
        {
            "name": "Bradycardia",
            "percent": "8"
        },
        {
            "name": "Feeling jittery",
            "percent": "8"
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Bacterial meningitis",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Anaphylactic reaction characterized by acute pyrexia",
            "percent": null
        },
        {
            "name": "respiratory distress",
            "percent": null
        },
        {
            "name": "bronchospasm",
            "percent": null
        },
        {
            "name": "hypoxemia",
            "percent": null
        },
        {
            "name": "perioral cyanosis",
            "percent": null
        },
        {
            "name": "tachycardia",
            "percent": null
        },
        {
            "name": "hypotension",
            "percent": null
        },
        {
            "name": "diarrhea",
            "percent": null
        },
        {
            "name": "and rash",
            "percent": null
        }
    ]
}